pharma · Obesity, Overweight · Type 2 Diabetes
Eli Lilly and
Eli Lilly Co.
Eli Lilly Co is a pharma organization headquartered in EU. Primary therapeutic focus areas include Obesity, Overweight, Type 2 Diabetes, Ulcerative Colitis, Type 2 Diabetes Mellitus, Breast Cancer. NovaPharmaNews links 1
Company details
- Status
- Public
- HQ
- Lilly Corporate Center, Indianapolis, Indiana 46285, US
- Founded
- 1876
- Employees
- 55,860
- Programs
- 107
- Drugs
- 99
- Patents
- 0
A Phase 1 Study on the effects of LY3410738 (...
Phase 1 · other · Patients with IDH1 R132, IDH2 R140 or IDH2 R172-mutant advanced solid tumor types, including but not limited to cholangiocarcinoma, chondrosarcoma, and glioma.
A Phase 1 Study on the effects of LY3410738 (... for Patients with IDH1 R132, IDH2 R140 or IDH2 R172-mutant advanced solid tumor types, including but not limited to cholangiocarcinoma, chondrosarcoma, and glioma. is a Phase 1 program (other) at Eli Lilly Co. with 1 ClinicalTrials.gov record(s).
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Eli Lilly Co.
- Phase
- Phase 1
- Modality
- other
- Indication
- Patients with IDH1 R132, IDH2 R140 or IDH2 R172-mutant advanced solid tumor types, including but not limited to cholangiocarcinoma, chondrosarcoma, and glioma.
- Status
- active
- Trials
- 1